Date: 2015-01-27
Type of information: Loan
Company: TxCell (France)
Investors: BpiFrance (France)
Amount: € 1.7 million
Funding type: loan
Planned used: The money is granted for clinical development of TxCell’s lead product candidate Ovasave®, for which a placebo-controlled phase IIb clinical study, CATS29, is ongoing in refractory Crohn’s disease. Top line results of this study are expected at the end of 2016 / early 2017.
Others: * On January 27, 2015,TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announced the receipt of € 1.7 million from Bpifrance. This support from Bpifrance for the clinical development of Ovasave is in the form of an interest-free innovation loan entitled Prêt à Taux Zéro pour l’Innovation (PTZI). This financing tool has been designed to support innovative French companies and is particularly attractive thanks to its complementarity to the French research tax credit system. As a result, the PTZI finance will provide TxCell with extended flexibility on its research and development activities.
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
